Trust Ventures is a venture capital firm that focuses on startups and provides knowledge and expertise in incumbent-heavy industries. The firm was founded in 2018 and is based in Austin, Texas, United States.

Trust Ventures

Andreessen Horowitz is a venture capital firm specializing in investing in seed, start-ups, early, mid-stage, growth, and late-stage. It prefers to invest in the social media business and technology sector with a focus on software, back-end infrastructure, the infrastructure of the Internet, cloud computing, enterprise software and services, consumer, business Internet, mobile-Internet, consumer Internet, cloud computing, data storage, social network browsers data-storage, consumer electronics, networking functions, software related biology, biotech, and medicine companies at the intersection of computer science and life sciences with a focus on digital therapeutics, cloud technology in biology, and computational medicine.

Andreessen Horowitz

Each Founder Collective partner has founded and sold a technology company. The company we wish had existed when we first started out is what we hope to create with Founder Collective. We offer a user guide for managing the risky commodity known as venture capital. The company believes that in order to advance their firms and maintain control, entrepreneurs should aim to raise the least amount of money possible. Founder Collective was established on May 22, 2009 in Cambridge, Massachusetts.

Founder Collective

Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC. It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor with expertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography. Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.

Alumni Ventures

Supernode Ventures they invest in early stage technology companies including fintech, software, digital media, family offices, SaaS companies, and hedge funds.

Supernode Ventures

Cleo Capital is a venture capital company. The company focuses on making investments in early-stage and expanding start-up businesses.

Cleo Capital

Shrug Capital is a Venture capital firm that invests in consumer-based startups. Shrug Capital was founded in 2018 and headquartered in San Francisco, California.

Shrug Capital

Incisive Ventures is a pre-seed investor focused on transformational founders. They invest in low-cost investment vehicles that boost LP returns in the asset class, especially compared to the classic Venture model. The company is a theme syndicate with high conviction but low volume.

Incisive Ventures

Spacecadet is The Marketing VC, investing in Spacecadets building moonshots and helping tell their stories.

Spacecadet Ventures

Awesome People Ventures operates as a ventures capital firm.

Awesome People Ventures

Audrey Capital is an angel investment and research company created by Matt Mullenweg of WordPress to help innovative ideas grow.

Audrey Capital

The Tribe

VC firm providing early stage capital and resources to transformational leaders focused on highly scalable opportunities.

Generation Ventures

Karman Ventures (fka Moving Capital) is a venture capital firm backed by early employees of Uber and other decacorn startups.

Karman Ventures (fka Moving Capital)

What If Ventures invests in stigmatized verticals within the healthcare market. For too long, stigma has artificially suppressed demand for care in indications such as mental health, fertility, and many others.  Societal changes are creating markets where stigma once stood in the way of people getting the care they need. The firm was founded in 2019 by Stephen Hays, after his own personal struggles with mental health and addiction fueled his desire to see more funding for solutions in that space.  Since then, the firm has broadened its aperture and has deployed nearly $80mm into more than 60 disruptive healthcare startups.

What If Ventures

AirAngels they are helping investing for engineering, product, growth, operations, brand, data science, marketplaces, international expansion, and policy.

AirAngels

Basement Fund specializes to invest in the early-stage.

Basement Fund

Diverse Angels is an angel group for current & aspiring investors from underrepresented and diverse backgrounds (People of Color, Women, LGBTQ+) to come together and share access to opportunities for ownership in early-stage tech companies. The mission to increase representation of diverse investors as a means to address the systemic wealth gaps, notably the racial wealth gap in the US. With a focus on bridging wealth gaps & disparities, Diverse Angels is a B-Corporation that is supported 100% by volunteers and charges no fees to the community though its 0/00 model.  This innovative 0/00 model (0% management fees are charged and 0% of carried interest - i.e. profit) was put into place to remove barriers and costs that could prevent diverse angels (especially first-timers) from participating in deals. The 0/00 model also ensures that the angels’ maximum amount of capital is deployed to allow for the maximum amount of upside. In search of the best founders, Diverse Angels leverages the size, strength, and diversity of its member base to maintain high standards of investment rigor. There are intentional efforts to source & meet founders from all backgrounds and it is a priority that the majority of Diverse Angels’ investments are made into Diverse Founders (People of Color, Women, LGBTQ+).

Diverse Angels

We are a specialized investment fund in biotechnology that also functions as a company builder. Our mission is to create and support innovative companies, guiding them from inception to commercial launch.  As a dynamic company builder, we provide support to emerging companies in agrowth-focused and innovative environment. We deliver comprehensive services in finance, accounting, legal, compliance, and recruitment to help startups thrive and succeed.

Saya Bio

TriplePoint Capital offers leases and loans to finance companies' equipment or growth-capital needs. The company offers debt-financing products, including equipment leases, equipment loans, and growth capital loans. The company's equipment leases and equipment loans are used to finance equipments, such as computers and servers, electronic test and measurement equipment, telecommunications equipment, laboratory equipment, office furniture, and software.

TriplePoint Capital

A16z crypto is a $300M venture fund that will invest in crypto companies and protocols. The company's fund is designed to include features of traditional venture capital, updated to the modern crypto world.

a16z crypto

Long Journey Ventures is an early-stage venture capital firm focused on early and new investments. It was founded in 2019 and is based in San Francisco, California, USA.

Long Journey Ventures

Levels

Levels develops a health and wellness platform designed to monitor metabolic fitness. The platform tracks blood glucose in real-time, enabling users to optimize their diet and exercise. The company was founded in 2019 and is a remote-first company.

Levels is a digital health company that provides a mobile app and continuous glucose monitoring (CGM) system to help users optimize their metabolic health. By combining real-time glucose data with food logging, activity tracking, and personalized recommendations, Levels enables users to manage their weight, improve energy levels, and reduce the risk of chronic diseases.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

<div>Levels is a developer of bio-wearable monitoring systems that measure users' metabolic fitness leveraging data based on individuals&rsquo; diets. The device also operates with a smartphone app that allows users to gain real-time access to their blood glucose levels. Users also receive regular insights from the Levels team via an app-based chat, which can positively affect the users&rsquo; health spans.</div>

Longevity Tech

Levels is a health and wellness company that offers a mobile app designed to help users optimize their metabolic health. The Levels app works in conjunction with a continuous glucose monitor (CGM) to provide personalized data about an individual's glucose levels and other biomarkers. The company aims to empower users to optimize their diet, sleep, and exercise routines based on this personalized data.

20 Health and Wellness Programs with a Different Purpose

List of Top 50 biggest Wellness Companies in the USA • BoldData

Top 10 Best Health & Wellness Companies In USA 2023

Global Wellness Institute

10 Best Employee Wellness Platforms Of 2024

30 Health & Wellness Industry Statistics For 2024 (+PDF Report)

Unlock Your Metabolic Health

Still feeling good: The US wellness market continues to boom

From counting steps to saving lives and beyond

Wearable Tech

Levels adds another $10m to advance metabolic health mission

<div>
 
 Levels is a developer of bio-wearable monitoring systems that measure users' metabolic fitness leveraging data based on the individuals&rsquo; diets. The device also operates with a smartphone app that allows users to gain real-time access to their blood glucose levels. Users also receive regular insights from the Levels team via app-based chat. 
 In April 2022, the company expanded its portfolio of services to include in-home blood testing to track metabolic biomarkers and offer guidance from a nutritionist.&nbsp;
 
 
 Also in April 2022, the firm concluded a USD 38 million Series A funding round mainly from operator investors including Andreessen Horowitz (a16z) and founders, pushing its valuation to USD 300 million. The funds were allocated to expand its commercial availability and to expand internationally in 2022. The company was previously available only to a beta testing community of 25,000 paid members.&nbsp;&nbsp;
 
 
 
 
 
</div>

Levels is a digital health company that provides a mobile app and continuous glucose monitoring (CGM) system to help users optimize their metabolic health. By combining real-time glucose data with food logging, activity tracking, and personalized recommendations, Levels enables users to manage their weight, improve energy levels, and reduce the risk of chronic diseases.The company also offers in-home blood testing to track key metabolic biomarkers for cardiovascular health, insulin resistance, and metabolic health and provides guidance from nutritionists to help users achieve their health goals.Key customers and partnershipsAs of August 2024, the company had over 60,000 members.&nbsp;

Cardiomo Care is developing noninvasive wearable devices to alert users and caretakers when there are abnormalities in the heartbeat. The company’s AI engine, trained on existing and growing data sets, can predict potential heart issues up to two hours before they occur, enabling early detection and intervention for arrhythmias and other cardiovascular diseases (CVDs).The company's product, CardiomoPatch, is a waterproof, wearable patch capable of long-term wear with a 10-day battery life. The patch monitors a patient's cardiac data, including ECG outputs, breathing, and skin temperature, and transmits the data via a mobile app for analysis by Cardiomo's AI engine.&nbsp;As of May 2024, the company is yet to commercialize its product and has over 1,600 pre-orders.

Cardiomo Care

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Omada Health

VillageMD provides primary care services for patients. It also provides tools, technology, and staffing support needed for physicians to deliver high-quality services. VillageMD’s service delivery methods include traditional freestanding clinics, Village Medical at Walgreens co-located clinics, as well as at-home and around-the-clock virtual visits. It also leverages a team-based approach to care where physicians lead nurse practitioners, pharmacists, mental health specialists, and dietitians to offer a holistic care program. The technology of VillageMD includes docOS, an operating system that enables better patient care by connecting various clinical source systems with ongoing patient-generated data coupled with an AI engine to continuously analyze messages to enable patient self-care.The company made several acquisitions to expand its footprint: 1) <a href="https://sp-edge.com/updates/14347">Summit Health</a> for USD 8.9 billion in November 2022, 2) Healthy Interactions, an interactive patient education platform, in February 2022, and 3) <a href="https://sp-edge.com/updates/16968">Starling Physicians</a>, a primary care and specialty care provider, in March 2023.Key customers and partnershipsIn June 2020, VillageMD and Walgreens Boots Alliance announced a collaborative effort to open at least 600 Village Medical centers at Walgreens across more than 30 US markets by 2025. Walgreens invested USD 5.2 billion in VillageMD (from the previously announced USD 1.0 billion), raising its ownership stake to 63% (from 30%).However, as of May 2024, Walgreens had plans to close 160 VillageMD clinics as part of a cost-cutting plan.

VillageMD

Cityblock Health is a value-based healthcare provider focused on delivering comprehensive care to underserved communities, primarily Medicaid and lower-income Medicare beneficiaries. The company combines primary care, behavioral health, and social services to address the complex physical, mental, and social needs of its members.Cityblock's model involves partnering with local community-based organizations and deploying multidisciplinary care teams that include doctors, nurses, behavioral health specialists, and community health workers. These teams provide personalized care through 24/7 access to multi-modal care delivery, including in-home visits, telehealth, and community health hubs.The services of Cityblock are available to members at no additional cost if they are covered by an eligible health plan.Key Customers and PartnershipsAs of May 2024, the company’s services were available in seven states across the US and served over 100,000 members.In May 2024, it partnered with <a href="https://sp-edge.com/updates/29647">Sunshine Health</a> to expand to Florida, and, in <a href="https://sp-edge.com/updates/13270">September 2022</a>, it partnered with MDwise to expand into Indiana. Prior to that, the company had partnered with insurance providers such as ConnectiCare (Connecticut), Tufts Health Plan (Massachusetts), Emblem Health (New York), Healthy Blue (North Carolina), Molina Healthcare (Ohio) and CareFirst (Washington DC).Funding and FinancialsCityblock is a spin-off of Sidewalk Labs, an Alphabet company that incubates and invests in tech companies and products to improve urban infrastructure. It completed a USD 400 million Series D funding round led by Softbank in <a href="https://sp-edge.com/updates/5326">September 2021</a>, valuing the company at USD 5.7 billion. The funds were used to expand its services.

Cityblock Health

Everside Health (formerly Paladina Health) offers preventative care for chronic conditions and primary, mental and occupational healthcare treatments for acute conditions. Patients benefit from around-the-clock access to care, same-day or next-day appointments for in-person, and virtual care visits with zero copays.Everside aims to generate around 17% healthcare cost savings in three years and 31% in five years for its corporate members by leveraging a data-driven approach to care coordination.The company leverages data from past medical records, predictive analytics, and AI in the delivery of preventative care services.Founded in 2010 under the name Paladina Health, the company was rebranded in November 2020 as Everside Health following a merger between three primary care groups (Paladina, Activate Healthcare, and Healthstat). Furthermore, in February 2024, Everside Health merged with primary care provider Marathon Health to form a combined entity that would operate as Marathon Health, and, as of May 2024, the integration was ongoing.Key customers and partnershipPost-merger with Marathon Health, the combined entity would serve 2.5 million patients through over 680 clinics across 41 states.Funding and financialsThe company received its most recent investment in July 2022, amounting to USD 164 million in growth equity funding. The round was led by New Enterprise Associates (NEA). The funds were allocated toward growing its market presence and exploring opportunities for M&amp;A as well as to enhance and improve its product features. Additionally, the firm planned to expand its coverage of specialty care services aimed at individuals, employers, and union organizations.

Everside Health

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

To gather large amounts of real-time data for chronic care management, DTx, and patient monitoring

XR used by some startups for chronic pain management

Offers digital means of providing direct primary care, passive remote monitoring, chronic care management, etc.

AI/ML is used in predictive analytics, diagnostics tools, and population management

Offers tailored preventive interventions and treatments to the specific needs and characteristics of each individual

<div>
 
 Levels is a developer of bio-wearable monitoring systems that measure users' metabolic fitness leveraging data based on individuals&rsquo; diets. The device also operates with a smartphone app that allows users to gain real-time access to their blood glucose levels. Users also receive regular insights from the Levels team via an app-based chat, which can positively affect the users&rsquo; health spans.
 
 
 
 
 In April 2022, the company expanded its portfolio of services to include in-home blood testing to track metabolic biomarkers and offer guidance from a nutritionist.&nbsp;
 
 
 
 
 Funding and financials
 
 
 
 
 In April 2022, the firm concluded a USD 38 million Series A funding round from operator investors, including Andreessen Horowitz (a16z) and founders, pushing its valuation to USD 300 million. The funds were allocated to expand its commercial availability and to expand internationally in 2022. The company was previously available only to a beta testing community of 25,000 paid members.&nbsp;&nbsp;
 
 
 
 
 
</div>

Mitrix Bio addresses mitochondrial dysfunction by developing bioreactor-grown mitochondria to be transplanted into the human body to regenerate organs, reverse age-related disease, and support other longevity therapies. Large-scale mitochondrial transfusion could potentially treat Alzheimer's, Parkinson's, AMD, glaucoma, infectious disease, and other age-related diseases, along with children's mitochondrial mutation diseases. The company believes that the same technique can be used in healing and reducing frailty for the aged, speeding healing of wounded soldiers, or combating aging itself. The company is developing technologies and infrastructure targeting to reverse mitochondrial mtDNA degeneration targeting parts of the body that most commonly experience mitochondrial dysfunction. The company has six programs at preclinical stages in its pipeline (as of October 2023). These programs are focused on immunology (infectious diseases), neurology (Alzheimer's/Parkinson’s), ophthalmology (AMD/glaucoma), dermatology (aking aging/wound healing), musculo-skeletal (sarcopenia, frailty), and organs (liver/kidney).

Mitrix Bio

Sierra Sciences engages in research to develop therapeutics targeting aging based on telomeres. These get shorter as people age and lead to various diseases. The company aims to extend the human lifespan and healthspan based on addressing telomere shortening as a solution to address effects of human aging. The company receives royalties from the sale of Product B, a nutraceutical supplement developed in a partnership and distributed through Isagenix. The company develops therapeutics focused on pharmaceuticals to slow and reverse the aging process, nutraceuticals to slow and reverse aging, telomere protection, telomere length measurement, cancer diagnostics, cancer treatments, telomerase gene therapy, immortal pet cloning, and human growth hormones.

Sierra Sciences

Turn.bio is a biotech company developing therapies based on epigenetic reprogramming and reverse cellular aging. The company develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. This is focused on reprogramming the epigenome to restore capabilities that are often lost with age. Its proprietary ERA Platform can reportedly be used to revitalize different cells throughout the body. The company is exploring its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis, and ophthalmology. The platform is claimed to enable control of the time, duration, and dosage of transcription factors to optimize the mRNA cocktail for each indication. This reportedly allows control of reprogramming, moving the epigenome to a more youthful state step-by-step by carefully pulsing the cell with the transcription factors. The company claims to have discovered that the use of quiescent stem cells can significantly help to repair or replace specific types of damaged tissue. In these cases, the company reportedly deploys its Artificial Niche (AN) technology to protect the stem cells. AN technology combines stem-cell biology with biomolecular materials engineering and micro-fabrication technologies to generate novel cell-culture platforms that mimic crucial biochemical or structural aspects of the niche. turn.bio’s novel eTurna Platform can reportedly deliver a variety of cargoes requiring different routes of administration and be fine-tuned and targeted to specific tissue and cells. Funding and financials In July 2022, biotech company VitaDAO made a USD 1,000,000 investment into turn.bio. The investment was intended to fund turn.bio’s preclinical efficacy testing phase for mRNA therapeutics for dermatological and ophthalmological longevity research.

Turn.bio

<div>
 
 AgeX Therapeutics is a biotech company engaged in the development and commercialization of novel therapeutics focused on aging.&nbsp;
 
 
 
 
 The company is building upon the foundation of its proprietary technologies, such as PureStem and induced Tissue Regeneration, to develop medicines targeting aging and related diseases. Through PureStem, the company claims to have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging. iTM is claimed to be the company's longevity platform intending to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.
 
 
 
 
 Its product pipeline includes two cell-based and two iTR-based product candidates in development: AGEX-BAT1 and AGEX-VASC1.
 
 
 AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders, such as type 2 (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy in the discovery stage of development, composed of young regenerative vascular-forming cells.&nbsp;
 
 
 
 
 The company was founded by leading gerontologist, bioentrepreneur, and Ph.D. holder Dr. Michael D. West,&nbsp; a highly-regarded pioneer in cellular aging, stem cell research, telomerase, and cloning.
 
 
 
 
 In August 2023, the company entered a merger agreement with Serina Therapeutics, a privately held, clinical-stage biotech company developing a pipeline of therapies for the treatment of Parkinson&rsquo;s disease and other neurological diseases. Under this, Serina merged with a wholly-owned subsidiary of AgeX therapeutics in an all-stock transaction. The combined company continues under the &ldquo;Serina Therapeutics&rdquo; name and focuses on advancing Serina&rsquo;s pipeline of small-molecule drug candidates targeting central nervous systems indications.
 
 
 
 
 Funding and financials
 
 
 
 
 The company recorded total revenue of USD 34 million in 2022, compared to USD 144 million in 2021 (77% decrease). This is due to absence of grant revenues in 2022, as opposed to 2021, where grant revenue was USD 104 million. Net loss reported for 2022 was USD 10.5 million, compared to the loss of USD 8.7 million recorded in the preceding year.
 
 
 
 
 
</div>

AgeX Therapeutics

<div>
 
 UNITY Biotechnology develops therapeutics targeting age-related diseases, particularly focusing on therapy in ophthalmologic diseases, including diabetic macular edema and age-related neurologic conditions.
 
 
 
 
 Its therapeutics are intended to selectively eliminate or modulate senescent cells to slow down, stop, or even reverse age-related disease and restore aging or damaged tissue to a more functionally healthy state. The approach is expected to remedy diseases of aging, such as retinopathies, neurodegenerative disorders, fibrosis, and cancer.&nbsp;
 
 
 
 
 The company&rsquo;s lead drug candidate, UBX1325, is evaluated for the treatment of age-related diseases of the eye, including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival. It is claimed that UBX1325 demonstrated a statistically significant and clinically meaningful improvement in mean best corrected visual acuity (BCVA) across 48 weeks compared to sham treatment in the Phase II BEHOLD study in patients with DME. A Phase IIb study (ASPIRE) was enrolling patients with DME to evaluate UBX1325 head-to-head against aflibercept.
 
 
 
 
 UNITY Biotechnology was also developing programs targeting the Tie2 signaling pathway for therapeutic benefit. Tie2 pathway activity declines with age and causes the loss of vascular barrier integrity and diseased blood vessel formation in the eye. The Tie2/VEGF bispecific molecule targets two pathways believed to be core to disease progression in DME and AMD. Another program directed at Tie2 activation is in preclinical studies for multiple indications.
 
 
 
 
 The company's neurology programs intend to explore new mechanisms for cognitive benefit, and the company licensed its &alpha;-Klotho program, UBX2089, to Jocasta Neuroscience for development and commercialization in cognitive dysfunction associated with neurological and psychiatric conditions.
 
 
 
 
 
</div>

UNITY Biotechnology

Companies conducting R&D on cell and gene therapies that aim to repair or replace dysfunctional cells to address the root cause of age-related diseases

Companies involved in the development of novel small molecules or chemical drugs that target specific proteins or pathways in the body to treat age-related diseases as well as the identification of existing drugs that can be repurposed for the treatment of such diseases

Platforms and tools that collect and analyze patient data to detect, prevent, and monitor age-related damage

Dietary supplements and wellness products that are developed through scientific approaches to slow down age-related damage

Companies developing therapies for age-related sensory deficiencies such as vision and hearing loss

Companies in the neurotechnology sector that develop tools such as neuroimaging and neurostimulation devices; pharmaceutical drugs and therapies aimed at treating age-related neurological conditions

Diagnostic tests and services focused on assessing the health of an individual's gut microbiome and their metabolic processes to identify internal age-related issues

Platforms and tools that provide personalized remedies for general well-being and to mitigate the risk of age-related diseases

Genomics is used for diagnostics and to offer tailored treatment for age-related diseases

Offers digital platforms and devices that allow individuals to measure, track, and potentially modify the physiological changes associated with aging

AL/ML is used in drug discovery and development as well as diagnostic tools to support longevity-related treatments

Levels is a health and wellness company that offers a mobile app designed to help users optimize their metabolic health. The Levels app works in conjunction with a continuous glucose monitor (CGM) to provide personalized data about an individual's glucose levels and other biomarkers. The company aims to empower users to optimize their diet, sleep, and exercise routines based on this personalized data.
Levels' approach involves using CGM technology to track users' glucose levels continuously. The Levels app then analyzes this data, along with other biomarkers, to provide insights and recommendations tailored to each user's unique physiology and lifestyle. By understanding how their body responds to different foods, activities, and sleep patterns, users can make informed decisions to improve their metabolic health and overall well-being.
The Levels program focuses on promoting healthy habits and lifestyle changes rather than treating specific medical conditions. The app and accompanying CGM device allow users to experiment with different dietary and activity choices and observe the real-time impact on their glucose levels and other biomarkers. This data-driven approach empowers users to find the optimal strategies for their individual needs and goals.

Biostrap is a company that provides scalable and customizable biosensor-based precision health monitoring solutions. Their innovative wearable devices, such as the Biostrap Kairos launched in July 2023, offer advanced autonomic nervous system analysis and quantification of the sympathetic and parasympathetic branches through wrist-worn devices. Kairos utilizes a high-sensitivity CMOS optical sensor to capture raw photoplethysmography (PPG) data, enabling accurate computation of biometrics like heart rate, heart rate variability (HRV), beat-to-beat intervals, respiratory rate, and sleep-related parameters.
Biostrap's key differentiator lies in its commitment to delivering clinically reliable nervous system analysis through detailed and transparent biometric measurements. The Spot Check feature provides real-time visualization of the underlying PPG signal, signal quality, and R-R intervals, granting untethered access to every data point captured. This configurability and data integrity attracted clients like the National Police Wellbeing Service (NPWS) in the UK for their sleep, fatigue, and recovery program.
Kairos underwent extensive testing by HRV experts and achieved impressive accuracy levels, comparable to ECG chest straps. The launch marked Biostrap's pivot from the consumer wearable market to offering configurable hardware and software solutions for enterprise and research purposes.

Biostrap

Caeden is a wearable technology company that develops smart bracelets focused on promoting mindfulness and reducing stress. Their flagship product, the Sona smart bracelet, combines fashion and technology by integrating an advanced heart rate sensor into a genuine leather bracelet design. Launched in May 2016, the Sona retailed for USD 200 and offered a unique "Resonance" program, consisting of various breathing exercises tailored for different moments throughout the user's day.
The Sona aimed to provide a reprieve from the fast-paced city life by enabling users to start their day with a moment of zen, find calm and focus before important meetings, and unwind after workouts through concentrated breathing exercises. Caeden's founders, Nora Levinson and David Watkins, believed that regular use of the Resonance program could help build the user's resistance to stress, addressing a significant health issue faced by many.
Differentiating itself from step-tracking devices like Fitbit and smartwatches acting as smartphone extensions, the Sona positioned itself as a luxury item powered by technology designed to improve the wearer's overall quality of life through mindfulness. With its discreet design concealing the technology, the Sona aimed to offer mindfulness without drawing attention to the wearer's use of a device for that purpose.

Caeden

MyKronoz is a Swiss company that specializes in producing innovative hybrid smartwatches. Their flagship product, the ZeTime, was first launched in 2017 after a successful crowdfunding campaign on Kickstarter. The ZeTime features a unique design that combines traditional mechanical watch hands with a full-color touchscreen display, allowing it to function as both an analog watch and a smartwatch.
The watch offers activity tracking capabilities, including monitoring steps, calories burned, and sleep patterns using built-in sensors such as an accelerometer and optical heart rate monitor. It also provides smartwatch functionalities like displaying notifications, controlling music playback, and viewing incoming calls. The ZeTime's mechanical hands intelligently adjust their position to avoid obstructing the touchscreen display when interacting with the device.
One of the key advantages of the ZeTime is its impressive battery life. In watch mode, the battery can last up to 30 days on a single charge, while the smartwatch mode offers around 3-4 days of usage. The device also allows users to customize watch faces, either by selecting from pre-set options or creating their own designs using templates or personal photos.
The ZeTime received praise for its innovative concept and strong battery life. Some reviews, however, criticized its half-baked operating system, unresponsive touchscreen, and inconsistent activity tracking. Despite these drawbacks, MyKronoz's hybrid smartwatches garnered global recognition for their unique approach to wearable technology.

MyKronoz

Ringly is a company that produces fashionable smart jewelry, primarily rings and bracelets, aimed at the female market. Their devices are designed to discreetly notify wearers of incoming calls, messages, and app notifications through vibrations and LED lights. The rings are made from materials like 14k gold, sterling silver, and semi-precious gemstones like onyx, labradorite, and moonstone.
Ringly's core product is a smart ring that connects to the user's smartphone via Bluetooth. Through the Ringly app, users can customize which notifications trigger the ring's vibrations and colored LED lights. The app supports over 100 apps like calls, texts, emails, calendar alerts, and social media platforms. The rings are water-resistant and have a battery life of 2-3 days.
While technologically simple, Ringly's rings prioritize a fashionable and discreet design over advanced features. The idea is to provide a stylish alternative to smartwatches that seamlessly blends into the user's wardrobe and lifestyle without being obtrusive. Ringly has focused on creating fashionable jewelry pieces that also offer practical notification capabilities.

Ringly

Healbe Corporation is a technology company that develops wearable devices and associated software for health and wellness monitoring. The company's flagship product is the Healbe GoBe, a smart band that utilizes proprietary FLOW Technology to automatically track various body parameters. The GoBe device employs a combination of sensors, including an accelerometer, piezo pressure sensor, and impedance sensor, along with advanced algorithms to provide insights into users' overall health.
The GoBe smart band is designed to automatically measure calorie intake through the skin, eliminating the need for manual food logging. It also tracks calories burned, hydration levels, stress levels, sleep quality, heart rate, blood pressure, and physical activity. In November 2015, Healbe introduced automatic hydration level monitoring to the GoBe device, making it the first wearable to offer this feature without requiring manual input of fluid consumption.
Healbe's technology adapts to individual body characteristics, providing personalized insights and recommendations. The device monitors hydration levels continuously and alerts users when they need to drink more water. It also tracks emotional stress and helps users correlate it with their body's physical responses. The GoBe smart band measures energy expenditure throughout the day, including basal metabolism, regardless of physical activity levels.
The company's latest model, the GoBe3, incorporates additional features such as EDA-based Neuroactivity tracking and physiological stress estimation. It also offers improved sleep tracking capabilities, including detailed analysis of sleep phases and smart alarm functions designed to wake users during optimal sleep stages.
Healbe has developed a companion mobile application that synchronizes with the GoBe device in real-time, allowing users to view and analyze their data. The app provides detailed information on various health parameters and offers integration with Google Fit for a more comprehensive health data ecosystem.

Healbe

Wearable devices in form factors, such as wristwear and rings, designed to monitor and track various aspects of a person's physical activity, health, and wellness

Wearable entertainment devices designed primarily for entertainment and leisure purposes. These come in the form of hearables, wearable cameras, personalized smart devices, etc.

Apparel that incorporate electronic components, sensors, and connectivity features to provide functionalities beyond traditional clothing and accessories

Specialized wearable devices designed for use in industrial and work settings. These include safety wearables that come in the form of head-mounted devices, smart gloves, exoskeletons, etc.

Wearable devices, which are designed to monitor, collect, and transmit various health-related data, and wearable assistive devices. These come in the form of cardiac monitoring devices, glucose monitors, wearable pulse oximeters, hearing impairment aids, visual aids, etc.

Enhances the user experience by enabling language translation, contextual awareness, and personalized recommendations, making wearables more versatile and user-centric

Leveraging technology to collect data about the user's activities, preferences, and health metrics before using this information to provide personalized experiences

Industrial wearables contribute to increased efficiency, safety, and productivity in industrial settings by providing real-time data and connectivity solutions for workers and equipment

Empowers wearable devices to continuously improve and adapt to user preferences, offering personalized insights and recommendations based on user data

Enhances the functionality of wearables and allows users to access and interact with data through various devices and services in the broader IoT ecosystem

<div>
 Levels, a metabolic health management firm, has secured USD 10 million in a Series A extension round. This includes USD 3 million from crowdfunding and contributions from Long Journey, a16z, among others.
 The fresh capital will support the expansion of the company's metabolic health app to a broader user base and aid in the continued development of its platform.
</div>

Levels

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless